{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"252.0","value":"295.2"},{"groupId":"OG001","spread":"321.9","value":"520.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"97"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"238.9","value":"263.9"},{"groupId":"OG001","spread":"360.3","value":"537.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"188.0","value":"236.1"},{"groupId":"OG001","spread":"415.0","value":"564.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"282.3","value":"256.4"},{"groupId":"OG001","spread":"396.7","value":"579.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"79"}],"units":"Participants"}],"title":"Cycle 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Brigatinib 90 mg, tablets, orally, once daily in each Cycle of 28 days until disease progression or intolerable toxicity (median duration of exposure was 402 days).","id":"OG000","title":"Brigatinib 90 mg"},{"description":"Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in Cycle 2 and onward Cycles of 28 days until disease progression or intolerable toxicity (median duration of exposure was 522 days).","id":"OG001","title":"Brigatinib 90 mg - 180 mg"}],"paramType":"MEAN","populationDescription":"ITT Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to the assigned dose. Here, number of participants analyzed is the participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Day 1 Cycles 2, 3, 4 and 5 (each Cycle of 28-days) pre-dose","title":"Pre-dose Brigatinib Plasma Concentration","type":"SECONDARY","unitOfMeasure":"ng/ml"}